{"organizations": [], "uuid": "9ad69316f79aec3ace4af442bfa758955a96526f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biocryst-pharmaceuticals-files-def/brief-biocryst-pharmaceuticals-files-definitive-proxy-statement-related-to-pending-merger-with-idera-pharmaceuticals-idUSFWN1RF09F", "country": "US", "domain_rank": 408, "title": "BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T15:07:00.000+03:00", "replies_count": 0, "uuid": "9ad69316f79aec3ace4af442bfa758955a96526f"}, "author": "", "url": "https://www.reuters.com/article/brief-biocryst-pharmaceuticals-files-def/brief-biocryst-pharmaceuticals-files-definitive-proxy-statement-related-to-pending-merger-with-idera-pharmaceuticals-idUSFWN1RF09F", "ord_in_thread": 0, "title": "BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "pending merger with idera pharmaceuticals reuters", "sentiment": "none"}, {"name": "biocryst pharmaceuticals inc", "sentiment": "none"}, {"name": "biocryst", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "idera pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2, 2018 / 12:09 PM / in a minute BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals Reuters Staff \nApril 2 (Reuters) - Biocryst Pharmaceuticals Inc : \n* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS \n* ‍BIOCRYST SPECIAL MEETING OF STOCKHOLDERS SCHEDULED FOR MAY 9, 2018​ \n* ‍RECOMMEND THAT ALL CO’S STOCKHOLDERS VOTE “FOR” MERGER PROPOSAL WITH IDERA PHARMA​ \n* ‍RECOMMEND STOCKHOLDERS VOTE “FOR” BIOCRYST PROPOSALS SET FORTH IN PROXY STATEMENT, INCLUDING “FOR” MERGER PROPOSAL​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-02T15:07:00.000+03:00", "crawled": "2018-04-02T15:17:19.031+03:00", "highlightTitle": ""}